Effects of ketoconazole on the polymorphic 4‐hydroxylations of S‐ mephenytoin and debrisoquine.
- 1 August 1989
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 28 (2) , 161-165
- https://doi.org/10.1111/j.1365-2125.1989.tb05409.x
Abstract
Studies were undertaken in 12 normal, male subjects to determine whether a metabolic interaction occurs between ketoconazole and mephenytoin. A single dose (400 mg) of ketoconazole produced a reduction in the 0-8 h urinary R/S ratio of mephenytoin following oral administration (100 mg) of racemic drug and after 28 daily doses the median value was further reduced to 42.9% of its baseline value. Within 7 days following discontinuation of ketoconazole the enantiomeric ratio had returned to its pre-study value. These findings are consistent with ketoconazole being a potent in vivo inhibitor of mephenytoin''s 4-hydroxylation and confirm the ability of such an interaction to be predicted by in vitro studies with human liver microsomes. By contrast, ketoconazole had a much smaller effect on the 0-8 h urinary metabolic ratio of debrisoquine, indicating that ketoconazole has a selective inhibitory effect on different forms of cytochrome P-450.This publication has 23 references indexed in Scilit:
- Clinical Pharmacokinetics of KetoconazoleClinical Pharmacokinetics, 1988
- Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.British Journal of Clinical Pharmacology, 1986
- Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.British Journal of Clinical Pharmacology, 1986
- Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.Published by Wiley ,1986
- Sparteine oxidation is practically abolished in quinidine-treated patients.British Journal of Clinical Pharmacology, 1986
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Substrate interaction with cytochrome P-450Pharmacology & Therapeutics, 1981